title: Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
abstract: BACKGROUND
  Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents – other than docetaxel – that are approved second-line treatments for non-small-cell lung cancer.
  
  
  METHODS
  The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.
  
  
  RESULTS
  Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar.
  
  
  CONCLUSIONS
  In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.
authors.affiliation: Department of Medicine (Lung), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Popat
authors.forename: Anders
authors.initials: A
authors.lastname: Mellemgaard
authors.forename: Kyle
authors.initials: K
authors.lastname: Fahrbach
authors.forename: Alison
authors.initials: A
authors.lastname: Martin
authors.forename: Maria
authors.initials: M
authors.lastname: Rizzo
authors.forename: Rolf
authors.initials: R
authors.lastname: Kaiser
authors.forename: Ingolf
authors.initials: I
authors.lastname: Griebsch
authors.forename: Martin
authors.initials: M
authors.lastname: Reck
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D019233:Retreatment; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D043823:Taxoids; D000077143:Docetaxel; D066246:ErbB Receptors; C530716:nintedanib
keywords: NSCLC; adenocarcinoma; chemotherapy; nintedanib; second-line treatment